Efavirenz Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Efavirenz Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
321
Registered trials
208
Result records
36
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Efavirenz can convert its Small molecule drug profile and RT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Efavirenz (query alias: efavirenz) |
|---|---|
| Modality / target | Small molecule drug; RT; RT inhibitors |
| Highest global status | Approved |
| Originator | Bristol Myers Squibb Co. |
| Active developers | Teva Pharmaceuticals Europe BV, Merck Sharp & Dohme LLC, MSD KK (Tokyo) |
The MCP disease footprint includes HIV Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07482085 | Phase 3 | Not yet recruiting | 246 | Median survival time |
| NCT07565441 | Phase 1 | Not yet recruiting | 112 | Maximum Plasma Concentration (Cmax) of JMKX003142 and its metabolites |
| NCT07570069 | Phase 1 | Active, not recruiting | 18 | Maximum Observed Plasma Concentration (Cmax) of SUZ and its Metabolite in the Absence and Presence of Efavirenz |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efavirenz 400 mg vs. 600 mg Combined with Lamivudine and Tenofovir in Treatment-Naïve HIV-Infected Patients in China: A Randomized, Multi-Centered, Controlled Trial
Phase 3; n=422; evaluation: Non-inferior. Reported fields: Virological suppression(72-week) = 84.1 % ; Virological suppression(72-week) = 86.5 %
A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas.
Phase 2; n=19; evaluation: not stated. Reported fields: -; -; Percentage of Patients in Non-progression at 2 Months = 14.3 percentage of participants (95% Confidence Interval, 1.8 - 42.8)
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSE ABROCITINIB ON THE PHARMACOKINETICS OF SINGLE DOSES OF CAFFEINE, EFAVIRENZ, AND OMEPRAZOLE IN HEALTHY PARTICIPANTS
Phase 1; n=26; evaluation: not stated. Reported fields: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Omeprazole(Geometric Mean): Ratio of Adjusted Geometric Means = 288.81(90% CI, 240.56 - 346.73); Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Omeprazole(Geometric Mean) = 688.8 ng*hr/mL (Geometric Coefficient of Variation, 90); Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Omeprazole(Geometric Mean) = 238.5 ng*hr/mL (Geometric Coefficient of Variation, 101)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Efavirenz addresses HIV Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 36 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: RT records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-12-20 | FDA will conduct an iPSP study on Abivax's obefazimod for the treatment of IBD. | Phase 3 | Financial terms not disclosed |
| 2022-07-27 | 复星医药与国药控股签署战略协议 加速推进阿兹夫定片全国渠道网络覆盖 | Approved | Financial terms not disclosed |
| 2022-07-25 | 复星医药与真实生物达成战略合作 联合开发及独家商业化阿兹夫定 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Cancer treatment with a her2 inhibitor and a CYP3a and/or p-gp modulator”. The milestone feed surfaced a patent-application signal described as “Antibody-drug conjugates for treating infections of human immunodeficiency virus (HIV)”. The milestone feed surfaced a patent-application signal described as “Products of manufacture and therapeutic compositions for treating, ameliorating or preventing viral infections and methods for making and using them”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
